Patrick Davey1, Mike G Kirby2. 1. Northampton General Hospital, Cliftonville, Northampton, NN1 5BD, UK. ppdavey@gmail.com. 2. Trends in Urology & Men's Health, Baldock, Herts, SG7 5DX, UK.
Abstract
PURPOSE: Androgen deprivation therapy (ADT) is the mainstay for the management of metastatic prostate cancer. Available pharmaceutical ADTs include gonadotropin-releasing hormone (GnRH) agonists and antagonists. Here, real-world data are presented from the UK general practitioner Optimum Patient Care Research Database. The study investigated the hypothesis that GnRH antagonists have lower cardiac event rates than GnRH agonists. METHODS: The incidence of cardiac events following initiation of GnRH antagonist or agonist therapy was investigated in a population-based cohort study conducted in UK primary care between 2010 and 2017. RESULTS: Analysis of real-world data from the UK primary care setting showed that relative risk of experiencing cardiac events was significantly lower with degarelix, a GnRH antagonist, compared with GnRH agonists (risk ratio: 0.39 [95% confidence interval 0.191, 0.799]; p = 0.01). Patients that received degarelix as first-line treatment switched treatment more frequently (33.7%), often to a GnRH agonist, than those who initiated treatment with a GnRH agonist (6.7-18.6%). CONCLUSION: Screening for known or underlying vascular disease and identifying those at high risk of a cardiac event is important for risk mitigation in patients with prostate cancer receiving hormone therapy. The GnRH antagonist degarelix conferred a significantly lower risk of cardiac events than GnRH agonists. Prior to treatment, patients should be stratified based on level of cardiovascular (CV) risk, and appropriate lifestyle, and pharmacological interventions to mitigate CV risk should be recommended. CV risk factors and patient response to the intervention should be monitored at regular intervals.
PURPOSE: Androgen deprivation therapy (ADT) is the mainstay for the management of metastatic prostate cancer. Available pharmaceutical ADTs include gonadotropin-releasing hormone (GnRH) agonists and antagonists. Here, real-world data are presented from the UK general practitioner Optimum Patient Care Research Database. The study investigated the hypothesis that GnRH antagonists have lower cardiac event rates than GnRH agonists. METHODS: The incidence of cardiac events following initiation of GnRH antagonist or agonist therapy was investigated in a population-based cohort study conducted in UK primary care between 2010 and 2017. RESULTS: Analysis of real-world data from the UK primary care setting showed that relative risk of experiencing cardiac events was significantly lower with degarelix, a GnRH antagonist, compared with GnRH agonists (risk ratio: 0.39 [95% confidence interval 0.191, 0.799]; p = 0.01). Patients that received degarelix as first-line treatment switched treatment more frequently (33.7%), often to a GnRH agonist, than those who initiated treatment with a GnRH agonist (6.7-18.6%). CONCLUSION: Screening for known or underlying vascular disease and identifying those at high risk of a cardiac event is important for risk mitigation in patients with prostate cancer receiving hormone therapy. The GnRH antagonist degarelix conferred a significantly lower risk of cardiac events than GnRH agonists. Prior to treatment, patients should be stratified based on level of cardiovascular (CV) risk, and appropriate lifestyle, and pharmacological interventions to mitigate CV risk should be recommended. CV risk factors and patient response to the intervention should be monitored at regular intervals.
Entities:
Keywords:
Cardiovascular; Degarelix; GnRH agonist; GnRH antagonist; Prostate cancer
Authors: Paul L Nguyen; Youjin Je; Fabio A B Schutz; Karen E Hoffman; Jim C Hu; Arti Parekh; Joshua A Beckman; Toni K Choueiri Journal: JAMA Date: 2011-12-07 Impact factor: 56.272
Authors: Neal D Shore; Fred Saad; Michael S Cookson; Daniel J George; Daniel R Saltzstein; Ronald Tutrone; Hideyuki Akaza; Alberto Bossi; David F van Veenhuyzen; Bryan Selby; Xiaolin Fan; Vicky Kang; Jackie Walling; Bertrand Tombal Journal: N Engl J Med Date: 2020-05-29 Impact factor: 91.245
Authors: Sarah N Hopmans; Wilhelmina C M Duivenvoorden; Geoff H Werstuck; Laurence Klotz; Jehonathan H Pinthus Journal: Urol Oncol Date: 2014-09-18 Impact factor: 3.498
Authors: Fernando E C Calais da Silva; Aldo V Bono; Peter Whelan; Maurizio Brausi; Anton Marques Queimadelos; Jose A Portillo Martin; Ziya Kirkali; Fernando M V Calais da Silva; Chris Robertson Journal: Eur Urol Date: 2009-02-21 Impact factor: 20.096
Authors: Derek J Rosario; Patrick Davey; James Green; Damien Greene; Bruce Turner; Heather Payne; Mike Kirby Journal: World J Urol Date: 2016-04-20 Impact factor: 4.226
Authors: Renato D Lopes; Celestia S Higano; Susan F Slovin; Adam J Nelson; Robert Bigelow; Per S Sørensen; Chiara Melloni; Shaun G Goodman; Christopher P Evans; Jan Nilsson; Deepak L Bhatt; Noel W Clarke; Tine K Olesen; Belinda T Doyle-Olsen; Henriette Kristensen; Lauren Arney; Matthew T Roe; John H Alexander Journal: Circulation Date: 2021-08-30 Impact factor: 39.918
Authors: Azariyas A Challa; Adam Christopher Calaway; Jennifer Cullen; Jorge Garcia; Nihar Desai; Neal L Weintraub; Anita Deswal; Shelby Kutty; Ajay Vallakati; Daniel Addison; Ragavendra Baliga; Courtney M Campbell; Avirup Guha Journal: Curr Treat Options Oncol Date: 2021-04-17
Authors: J Lehmann; C W Kluike; A Haider; K S Haider; S Baumann; M Flesch; M Gedamke; D Kägebein Journal: Urologe A Date: 2021-08-17 Impact factor: 0.639
Authors: Alessandro Sciarra; Gian Maria Busetto; Stefano Salciccia; Francesco Del Giudice; Martina Maggi; Felice Crocetto; Matteo Ferro; Ettore De Berardinis; Roberto Mario Scarpa; Francesco Porpiglia; Luca Carmignani; Rocco Damiano; Walter Artibani; Giuseppe Carrieri Journal: Front Endocrinol (Lausanne) Date: 2021-06-14 Impact factor: 5.555